Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback